Adalimumab (Humira®)

Assessment Status Rapid Review Complete
Drug Adalimumab
Brand Humira®
Indication In combination with methotrexate for polyarticular juvenile idiopathic arthritis in children and adolescents (4-17yrs) in patients who have had an inadequate response to DMARDs.  Also licensed as monotherapy in cases of intolerance to MTX or when continued therapy with MTX is inappropriate.
Assessment Process
Rapid review commissioned 20/05/2011
Rapid review completed 02/06/2011
Rapid review outcome Full Pharmacoeconomic Evaluation not Recommended